-
PurposeHypoxia response element real-time luciferase reporter
-
Depositing Lab
-
Depositing OrganizationWistar Institute
Located in the United States of America -
Citations
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 128096 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
| DNA | 128096-D50 | 50 μg of DNA in Tris buffer | $495 | ||
| DNA | 128096-D100 | 100 μg of DNA in Tris buffer | $585 | ||
Backbone
-
Vector backbonepGL4.22
-
Backbone manufacturerPromega
- Backbone size w/o insert (bp) 5570
- Total vector size (bp) 5779
-
Modifications to backboneinsertion of the VEGF HRE (x5) into promoter region
-
Vector typeMammalian Expression, Luciferase
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Growth instructionsThe depositing lab used Top10 in their studies.
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameHypoxia response element (x5) from VEGF promoter
-
Alt nameHRE (x5), HIF response element (x5)
-
Alt namevascular endothelial growth factor hypoxia response element (x3)
-
Alt nameVEGF, VEGFA
-
SpeciesH. sapiens (human)
-
Insert Size (bp)208
-
GenBank IDNM_001025366
-
Entrez GeneVEGFA (a.k.a. L-VEGF, MVCD1, VEGF, VPF)
- Promoter inserted VEGF hypoxia response elements (HRE) (x5)
-
Tag
/ Fusion Protein
- drives expression of destabilized luciferase (2CP) for real-time HRE activity assessment (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site xhoI (not destroyed)
- 3′ cloning site BglII (not destroyed)
- 5′ sequencing primer RVprimer3: CTAGCAAAATAGGCTGTCCC
- (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made by5HRE/GFP (Martin Brown and Thomas Foster, Addgene plasmid #46926) and pGL4.22 (Promega)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
DNA (Catalog # 128096-D50)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 50 μg
- Concentration 1 μg/μL
- Pricing $495 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
DNA (Catalog # 128096-D100)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 100 μg
- Concentration 1 μg/μL
- Pricing $585 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pGL4.22-VEGF-HRE::dLUC was a gift from Chi Van Dang (Addgene plasmid # 128096 ; http://n2t.net/addgene:128096 ; RRID:Addgene_128096) -
For your References section:
Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR. Walton ZE, Patel CH, Brooks RC, Yu Y, Ibrahim-Hashim A, Riddle M, Porcu A, Jiang T, Ecker BL, Tameire F, Koumenis C, Weeraratna AT, Welsh DK, Gillies R, Alwine JC, Zhang L, Powell JD, Dang CV. Cell. 2018 Jun 28;174(1):72-87.e32. doi: 10.1016/j.cell.2018.05.009. Epub 2018 May 31. 10.1016/j.cell.2018.05.009 PubMed 29861175